The burgeoning world of medical technology and innovative pharmaceuticals is woven with thousands of intricate joint ventures and acquisitions among huge established innovators and nimble emerging stars.
With the advent of recent severe pricing and comparative effectiveness limitations imposed by the Inflation Reduction Act, the new European Drug legislation and an unstable investment climate, potentially explosive disagreements threaten to disrupt many promising development and commercialization ventures.
What we address here is how to keep the delicate dance of business marriage from tripping into sadly predictable implosions — most often created by discordant compliance cultures and conflicting visions.
